GLYCO-IMMUNE CHECKPOINT INHIBITORS
Targeting Glycan-Sensing Checkpoints to Unleash Both the Innate and Adaptive Immune Responses to Cancer
GLYCO-IMMUNE CHECKPOINT INHIBITORS
The Need
Despite the early success of first-generation immuno-oncology drugs, most cancer patients still do not achieve clinical responses.
The Scientific Opportunity
Cell surface glycosylation is now known to play a central role in immuno-oncology: Tumor cells evolve over time, cloaking themselves in certain glycan patterns that down-regulate a wide spectrum of innate and adaptive immune cell types which are critical to fighting cancer.
The Approach
Palleon Pharmaceuticals has integrated technologies and insights from world-renowned scientific leaders in glycoscience and human immunology to create the first Glyco-Immune Checkpoint Inhibitors to treat cancer patients.
News
Palleon Pharmaceuticals Announces Preclinical Data from EAGLE Platform to be Presented at the AACR Special Conference on Tumor Immunology and Immunotherapy
November 08, 2018Palleon Pharmaceuticals Announces Preclinical Data from EAGLE Platform to be Presented at the Society for Immunotherapy of Cancer Annual Meeting
Twitter
@Palleon_Pharma
Looking for exciting, new opportunities in 2019? Come join us at Palleon, where you'll be able to advance a new are… http://hsWHenff6D
@Palleon_Pharma
This week we’ll be attending the largest annual gathering for protein science researchers in the world— The 18th An… http://qNAcgT3a3L